Autolus Therapeutics (AUTL) Operating Expenses: 2017-2025
Historic Operating Expenses for Autolus Therapeutics (AUTL) over the last 8 years, with Sep 2025 value amounting to $92.8 million.
- Autolus Therapeutics' Operating Expenses rose 36.74% to $92.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.1 million, marking a year-over-year decrease of 34.44%. This contributed to the annual value of $251.5 million for FY2024, which is 38.67% up from last year.
- According to the latest figures from Q3 2025, Autolus Therapeutics' Operating Expenses is $92.8 million, which was up 13.00% from $82.1 million recorded in Q2 2025.
- Autolus Therapeutics' Operating Expenses' 5-year high stood at $320.2 million during Q4 2023, with a 5-year trough of -$40.4 billion in Q3 2021.
- Its 3-year average for Operating Expenses is $62.0 million, with a median of $67.9 million in 2024.
- As far as peak fluctuations go, Autolus Therapeutics' Operating Expenses slumped by 94,390.49% in 2021, and later soared by 2,040.47% in 2023.
- Autolus Therapeutics' Operating Expenses (Quarterly) stood at $71.8 million in 2021, then plummeted by 79.17% to $15.0 million in 2022, then spiked by 2,040.47% to $320.2 million in 2023, then plummeted by 76.30% to $75.9 million in 2024, then spiked by 36.74% to $92.8 million in 2025.
- Its Operating Expenses was $92.8 million in Q3 2025, compared to $82.1 million in Q2 2025 and $74.2 million in Q1 2025.